LB Pharmaceuticals Q2 Loss Per Share Narrows

MT Newswires Live08-11

LB Pharmaceuticals (LBRX) reported Tuesday that its Q2 net loss per share narrowed to $1.71, from a loss of $13.58 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.80 per share.

As of June 30, the company had $327.8 million in cash, cash equivalents and marketable securities.

It said this balance excludes net proceeds from a $150 million private placement completed in July and, based on its current operating assumptions, expects to fund operations beyond Q2 2029.

The company's net loss widened to $51.6 million from $4.9 million a year earlier, as research and development expenses rose sharply, primarily due to its Phase 3 schizophrenia trial.

LB Pharmaceuticals also said it now expects topline data from that trial in the first half of 2027, earlier than previously forecast.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment